Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapy in Malignant Mesothelioma: What’s Up, Doc?

Chemotherapy in Malignant Mesothelioma: What’s Up, Doc? EDITORIAL Chemotherapy in Malignant Mesothelioma: What’s Up, Doc? Jan P. van Meerbeeck, MD, PhD (J Thorac Oncol. 2006;1: 279–280) wo randomized trials have now established the combination of cisplatin and an Tantifolate—pemetrexed or raltitrexed—as the standard in the systemic therapy for 1,2 mesothelioma. There remains however a large number of issues to be addressed. Not the least is whether the choice of the control arm in both trials was appropriate, in the absence of studies having compared active supportive care (ASC) with and without chemotherapy. An ongoing study by the British Medical Research Council (MRC)—randomizing between ASC, ASC with single agent vinorelbine and ASC with mitomycin, vindesine and cisplatin (MVP)—will hopefully address the issue in analogy to what has been observed in non-small cell lung cancer (NSCLC). In the mean time, indirect evidence comes from both abovementioned trials, as it is unlikely that single agent cisplatin will reduce survival in this patient population. Furthermore, a recent small randomized study comes closest to answering the question. Good performance patients with stable symp- toms were randomized between immediate chemotherapy, consisting of MVP, or the same chemotherapy at symptomatic progression. In the latter arm, chemotherapy was delayed with a median of 4 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Chemotherapy in Malignant Mesothelioma: What’s Up, Doc?

van Meerbeeck, Jan P.
Journal of Thoracic Oncology , Volume 1 (4) – May 1, 2006
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/chemotherapy-in-malignant-mesothelioma-colon-what-s-up-doc-p01TjGPhxL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

EDITORIAL Chemotherapy in Malignant Mesothelioma: What’s Up, Doc? Jan P. van Meerbeeck, MD, PhD (J Thorac Oncol. 2006;1: 279–280) wo randomized trials have now established the combination of cisplatin and an Tantifolate—pemetrexed or raltitrexed—as the standard in the systemic therapy for 1,2 mesothelioma. There remains however a large number of issues to be addressed. Not the least is whether the choice of the control arm in both trials was appropriate, in the absence of studies having compared active supportive care (ASC) with and without chemotherapy. An ongoing study by the British Medical Research Council (MRC)—randomizing between ASC, ASC with single agent vinorelbine and ASC with mitomycin, vindesine and cisplatin (MVP)—will hopefully address the issue in analogy to what has been observed in non-small cell lung cancer (NSCLC). In the mean time, indirect evidence comes from both abovementioned trials, as it is unlikely that single agent cisplatin will reduce survival in this patient population. Furthermore, a recent small randomized study comes closest to answering the question. Good performance patients with stable symp- toms were randomized between immediate chemotherapy, consisting of MVP, or the same chemotherapy at symptomatic progression. In the latter arm, chemotherapy was delayed with a median of 4

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2006

There are no references for this article.